Validation of suspected somatic single nucleotide variations in the brain of Alzheimer’s disease patients

February 16, 2017 - Madrid, Spain - It has been proposed that somatic gene variations (SNV) present in few brain cells could facilitate the development of neurodegenerative disorders like Alzheimer’s disease. Testing that hypothesis requires DNA sequencing directly in brain cells or tissue rather than in blood cells. However, the identification of SNV by standard and reliable sequencing procedures does not work well when the number of cells bearing the specific SNV (or mutation) is very low within the tissue. In this way, another techniques, such as high-throughput methods, could be used. However, those methods can introduce errors in reading sequence alignments that can interfere with the identification of true somatic variations. More...

February 16, 2017

Is it Depression or Dementia? Brain SPECT Imaging Helps Distinguish Them

Neuroimaging of decreased blood flow in specific regions of the brain can differentiate between depression and cognitive disorders, according to a new report in the Journal of Alzheimer’s Disease

February 15, 2017 - Amsterdam, NL – Does a patient have depression or a cognitive disorder (CD) such as Alzheimer’s disease or both? Since both disorders have overlapping symptoms, how can a clinician tell them apart to make an appropriate diagnosis? In a new article published in the Journal of Alzheimer’s Disease, researchers have found that single photon emission computed tomography, or SPECT, can help to distinguish between these diagnostic categories. More...

February 15, 2017

Altmetric Data Analysis Reveals How Parkinson’s Disease Research Affects the World

February 13, 2017 - London, UK and Boston, USA - ÜberResearch and Altmetric, leading data and analytics companies serving scientific funders and research organizations, have published an analysis of Parkinson’s disease research papers with the highest Altmetric Attention Scores in the Journal of Parkinson’s Disease. More...

February 13, 2017

Deep Brain Stimulation Studies in Alzheimer’s Disease Pose Ethical Challenges

Penn researchers propose guidelines to better protect patients in DBS clinical trials

January 30, 2017 - Promising, early studies of deep brain stimulation (DBS) for the treatment of Alzheimer’s disease have paved a path for future clinical trials, but there are unique ethical challenges with this vulnerable population regarding decision making and post-study treatment access that need to be addressed as they ramp up, Penn Medicine researchers argue in a new review in the Journal of Alzheimer’s Disease. More...

January 30, 2017